Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase Ib/IIa study of Pt(0506)101 + capecitabine + sintilimab in gastric and gastroesophageal junction adenocarcinoma
CTR20251082Phase 2Active
- Sponsor
- Beijing Shuobai Pharmaceutical Technology
- Start
- Aug 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of Pt(0506)101 in gastric adenocarcinoma, gastroesophageal junction adenocarcinoma, sponsored by Beijing Shuobai Pharmaceutical Technology. Started Aug 2025; status: active.
02
Drugs
Pt(0506)101
03
Conditions
gastric adenocarcinomagastroesophageal junction adenocarcinoma
Beyond the preview
Go deeper on CTR20251082.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20251082.